Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo™) inhaler

Headache

Volumn 48, Issue 3, 2008, Pages 355-367

  Shrewsbury, Stephen B ^a   Cook, Robert O ^a   Taylor, Glyn ^b   Edwards, Ceri ^c   Ramadan, Nabih M ^d  

^a MAP Pharmaceuticals Inc   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c SIMBEC RESEARCH LTD   (United Kingdom)

^d ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Aerosol; Dihydroergotamine mesylate; Migraine; Pharmacokinetics; Pressurized metered dose inhaler; Pulmonary

Indexed keywords

8' HYDROXYDIHYDROERGOTAMINE; DIHYDROERGOTAMINE MESILATE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AEROSOL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HEMATOLOGICAL PARAMETERS; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MONITORING; NAUSEA; NORMAL HUMAN; PARESTHESIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; SPIROMETRY; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TANDEM MASS SPECTROMETRY; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOMITING;

ADMINISTRATION, INHALATION; ADULT; ANALGESICS, NON-NARCOTIC; AREA UNDER CURVE; DIHYDROERGOTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METERED DOSE INHALERS;

EID: 42049084630     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.01006.x     Document Type: Article

References (16)

1. Valade D. Headaches in the emergency room. In : Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd edn. Baltimore, MD : Lippincott, Williams & Wilkins 2006 : 1133 1138.
2. Dowson AJ, Tepper SJ, Dahlof C. Patients' preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine. J Headache Pain. 2005 6 : 112 120.
3. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 55 : 754 762.
4. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006 46 : S171 S181.
5. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: Potential for a larger role. Headache. 2006 46 (Suppl. 4 S212 S220.
6. Wyss PA, Rosenthaler J, Neusch E, Aellig WH. Pharmacokinetics investigation of oral and IV dihydroergotamine in healthy subjects. Eur J Clin Pharmacol. 1991 41 : 597 602.
7. Maurer G, Frick W. Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. Eur J Clin Pharmacol. 1984 26 : 463 470.
8. Bendtsen L, Jensen R, Lipton RB, Bigal ME. Migraine: Epidemiology, impact, and risk factors for progression. Headache. 2005 45 (Suppl.1 S3 S13.
9. Bendtsen L, Jensen R. Prevalence, burden, and cost of headache disorders. Curr Opin Neurol. 2006 19 : 281 285.
10. Goadsby PJ, Lipton RA, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002 346 : 257 270.
11. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001 358 : 1668 1675.
12. Scott A. Dihydroergotamine: A review of its use in the treatment of migraines and other headaches. Clin Neuropharmacol. 1992 15 : 289 296.
13. Cook RO, Shrewsbury SB, Ramadan N. Dihydroergotamine mesylate via a novel system (Tempo™ inhaler). Poster presented at the National Headache Foundation, Palm Springs, CA, 2007.
14. Karch FE, Lasagna L. Adverse drug reactions. JAMA. 1975 234 : 1236 1241.
15. Bobick A, Jennings G, Skews H, Esler M, McLean A. Low oral bioavailability of dihydroergotamine and first-pass extraction with orthostatic hypotension. Clin Pharmacol Ther. 1981 30 : 673 679.
16. Schran HF, Tse FLS, Chang C-T. Bioequivalence and safety of subcutaneously and intramuscularly administered dihydroergotamine in healthy volunteers. Curr Ther Res. 1994 55 : 1501 1508.